Drugs / CH-1504
CH-1504
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00658047 | Apr 2008 → Feb 2009 | rheumatoid arthritis | Chelsea Therapeutics | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CH-1504 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00658047 ↗ |
| Known as | AA-243 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802141 ↗ |
| Known as | M-trex | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802141 ↗ |
| Known as | Mobiletrex | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802141 ↗ |
| Known as | Tridam | ChEMBL registry synonym — accepted as the source's own label CHEMBL4802141 ↗ |
| Action | Inhibit | “via folate enzyme inhibition” NCT00658047 ↗ |
| Modality | Other / unclassified | “CH-1504, a metabolically stable antifolate” PMID 21724705 ↗ Jul 2011 |
| Route | Oral | “CH-1504 (0.25 mg, 0.5 mg, or 1.0 mg once-daily oral doses)” PMID 21724705 ↗ Jul 2011 |